Neuphoria Therapeutics Inc.
NEUPHealthcare|Biotechnology|US
$2.78
+0.01 (+0.36%)
DCF Value
$3103.96
Tangible Book / Share
$3.13
Cash / Share
$3.67
Financials
Financial Snapshot
Market Cap
$15.0M
Enterprise Value
-$4.8M
Revenue (TTM)
$1.2M
Net Income (TTM)
-$18.5M
Cash & Investments
$19.9M
Net Cash
$19.8M
Free Cash Flow (TTM)
-$12.35B
Operating CF (TTM)
-$12.35B
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$19.9M
Quarterly Burn
$3.09B
Monthly Burn
$1.03B
Est. Runway
~0.0 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $33.4M | $18.7M | $10.2M | $3.1M | $21.4M | $33.6M | $8.1M | $12.6M | $21.6M | $19.87B | $19.9M | |
| Operating Cash Flow | -$1.4M | -$15.0M | -$10.9M | -$2.7M | -$5.7M | -$21.8M | -$9.8M | -$14.7M | $77.2M | -$12.35B | -$12.35B | |
| Free Cash Flow | -$1.7M | -$15.4M | -$11.0M | -$2.7M | -$5.7M | -$21.8M | -$9.8M | -$14.7M | $77.2M | -$12.35B | -$12.35B | |
| Capital Expenditure | -$247.5K | -$358.1K | -$69.3K | -$5.3K | -$1.1K | -$1.5K | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | |
| Financing Cash Flow | -$2.1M | $1.9M | $3.0M | -$3.7M | $23.7M | $27.0M | $5.8M | $15.1M | $1.53B | $17.92B | $18.7M |
R&D Spending
R&D (TTM)
$6.0M
R&D Intensity
512.7%
R&D Growth vs Prior
-99.8%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.1M | $11.9M | $7.4M | $32.1K | $927.5K | $383.2K | $0.00 | $0.00 | $15.6M | $1.2M | $1.2M | |
| R&D Expense | $18.6M | $18.5M | $6.3M | $4.0M | $4.3M | $23.3M | $19.7M | $14.1M | $9.0M | $3.55B | $6.0M | |
| R&D % of Revenue | 68.6% | 155.3% | 85.0% | 12489.6% | 466.8% | 6068.7% | — | — | 57.5% | 301952.5% | 512.7% | |
| SG&A | $5.7M | $5.0M | $6.6M | $3.3M | $4.2M | $7.7M | $13.4M | $8.5M | $7.8M | $7.44B | $9.6M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.1M | $11.9M | $7.4M | $32.1K | $927.5K | $383.2K | $0.00 | $0.00 | $15.6M | $1.2M | $1.2M | |
| Cost of Revenue | $24.2M | $25.4M | $12.1M | $0.00 | $1.7M | $16.0M | $671.5K | $663.0K | $662.9K | $663.0K | $663.0K | |
| Gross Profit | $2.8M | -$13.4M | $2.7M | $32.1K | -$1.3M | -$10.0M | -$671.5K | -$663.0K | $15.0M | $511.2K | $511.2K | |
| R&D | $18.6M | $18.5M | $6.3M | $4.0M | $4.3M | $23.3M | $19.7M | $14.1M | $9.0M | $3.55B | $6.0M | |
| SG&A | $5.7M | $5.0M | $6.6M | $3.3M | $4.2M | $7.7M | $13.4M | $8.5M | $7.8M | $7.44B | $9.6M | |
| Operating Income | -$13.8M | -$21.3M | -$10.8M | -$6.2M | -$9.0M | -$31.0M | -$33.1M | -$26.8M | -$1.1M | -$9.8M | -$13.9M | |
| Interest Expense | $1.5M | $1.5M | $1.7M | $1.2M | $1.1M | $26.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$4.8M | -$19.3M | -$6.9M | -$4.1M | -$6.7M | -$31.9M | -$32.4M | -$15.6M | -$838.0K | -$13.6M | -$18.7M | |
| Net Income | -$5.2M | -$18.4M | -$6.8M | -$4.9M | -$6.5M | -$22.9M | -$32.2M | -$15.5M | -$369.6K | -$13.5M | -$18.5M | |
| EPS (Diluted) | -0.13 | -0.46 | -0.16 | -0.11 | -0.10 | -0.20 | -0.24 | -0.10 | -0.23 | -3.06 | -7.26 | |
| EBITDA | -$3.7M | -$22.4M | -$11.2M | -$1.2M | -$4.5M | -$30.8M | -$31.5M | -$26.0M | -$466.2K | -$9.1M | -$12.7M | |
| Shares Out. (M) | 40.11 | 40.19 | 43.44 | 45.41 | 65.00 | 112.78 | 122.39 | 149.80 | 1.62 | 4.40 | 5.41 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.9M | $18.3M | $9.8M | $3.1M | $21.4M | $33.6M | $8.1M | $12.6M | $21.6M | $19.87B | $19.9M | |
| Short-Term Investments | $422.6K | $404.0K | $385.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $41.9M | $26.4M | $17.6M | $5.7M | $23.2M | $41.8M | $8.9M | $13.2M | $22.9M | $21.07B | $21.1M | |
| Total Assets | $64.6M | $47.8M | $37.6M | $23.7M | $40.8M | $65.3M | $19.4M | $27.6M | $43.4M | $28.71B | $28.7M | |
| Total Current Liabilities | $10.7M | $9.8M | $9.7M | $5.7M | $1.8M | $3.4M | $4.1M | $3.8M | $6.4M | $756.6M | $756.6K | |
| Long-Term Debt | $7.7M | $11.6M | $6.1M | $4.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $33.5M | $35.3M | $25.2M | $15.0M | $5.0M | $8.4M | $4.7M | $10.2M | $14.6M | $4.11B | $4.1M | |
| Stockholders' Equity | $31.1M | $12.5M | $12.4M | $8.7M | $35.8M | $56.9M | $14.7M | $17.5M | $28.9M | $24.60B | $24.6M | |
| Retained Earnings | -$83.1M | -$96.5M | -$98.7M | -$102.3M | -$115.7M | -$173.3M | -$108.2M | -$178.0M | -$271.0M | -$191.80B | -$191.8M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M | -$15.0M | -$10.9M | -$2.7M | -$5.7M | -$21.8M | -$9.8M | -$14.7M | $77.2M | -$12.35B | -$12.35B | |
| Capital Expenditure | -$247.5K | -$358.1K | -$69.3K | -$5.3K | -$1.1K | -$1.5K | $0.00 | $0.00 | $0.00 | $4.00 | $0.00 | |
| Free Cash Flow | -$1.7M | -$15.4M | -$11.0M | -$2.7M | -$5.7M | -$21.8M | -$9.8M | -$14.7M | $77.2M | -$12.35B | -$12.35B | |
| Investing Cash Flow | $953.9K | $59.7K | $138.4K | -$134.1K | -$60.3K | $621.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | -$2.1M | $1.9M | $3.0M | -$3.7M | $23.7M | $27.0M | $5.8M | $15.1M | $1.53B | $17.92B | $18.7M | |
| Issuance of Stock | $110.4K | $302.0K | $9.9M | $2.8M | $32.9M | $32.9M | $2.6M | $10.1M | $1.5M | $17.9M | $26.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$1.7M | $1.6M | -$3.7M | -$5.7M | -$8.9M | -$174.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $38.0K | $983.0K | $2.8M | $0.00 | $814.8K | $163.8M | $351.6M | $351.5M | |
| Net Change in Cash | -$2.6M | -$13.2M | -$7.7M | -$6.5M | $18.0M | $5.1M | -$15.0M | $505.0K | $1.60B | $5.58B | $5.6M |
Dilution Tracker
Shares Outstanding
5M
5-Year Share Growth
-93.2%
Stock Issuance (TTM)
$26.1M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 40.11 | 40.19 | 43.44 | 45.41 | 65.00 | 112.78 | 122.39 | 149.80 | 1.62 | 4.40 | 5.41 | |
| Change vs Prior % | — | 0.2% | 8.1% | 4.5% | 43.1% | 73.5% | 8.5% | 22.4% | -98.9% | 170.9% | 23.1% | |
| Stock Issuance | $110.4K | $302.0K | $9.9M | $2.8M | $32.9M | $32.9M | $2.6M | $10.1M | $1.5M | $17.9M | $26.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $38.0K | $983.0K | $2.8M | $0.00 | $814.8K | $163.8M | $351.6M | $351.5M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 10.4% | -112.5% | 36.2% | 100.0% | -136.7% | -2604.4% | — | — | 95.8% | 43.5% | 43.5% | |
| Operating Margin % | -51.0% | -178.2% | -145.5% | -19319.3% | -965.7% | -8095.2% | — | — | -7.2% | -835.5% | -1187.7% | |
| Net Margin % | -19.1% | -154.3% | -91.6% | -15255.2% | -704.5% | -5986.9% | — | — | -2.4% | -1145.7% | -1578.4% | |
| EBITDA Margin % | -13.5% | -187.3% | -151.6% | -3833.7% | -486.8% | -8026.6% | — | — | -3.0% | -779.1% | -1084.7% | |
| FCF Margin % | -6.2% | -128.8% | -148.5% | -8381.4% | -610.8% | -5677.8% | — | — | 493.5% | -1052073.1% | -1052118.7% | |
| ROE % | -16.7% | -147.9% | -54.6% | -56.1% | -18.3% | -40.3% | -219.7% | -88.6% | -1.3% | -0.1% | -77.0% | |
| ROA % | -8.0% | -38.6% | -18.0% | -20.7% | -16.0% | -35.1% | -165.9% | -56.0% | -0.9% | -0.0% | -64.6% | |
| ROIC % | -22.9% | -48.1% | -31.0% | -27.1% | -22.4% | -49.5% | -211.5% | -111.1% | -1.3% | -0.0% | -49.4% | |
| R&D / Revenue % | 68.6% | 155.3% | 85.0% | 12489.6% | 466.8% | 6068.7% | — | — | 57.5% | 301952.5% | 512.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 420.5% | -56.0% | -38.1% | -99.6% | 2793.0% | -58.7% | -100.0% | 0.0% | 0.0% | -92.5% | |
| Gross Profit | -45.6% | -573.9% | 119.9% | -98.8% | -4055.9% | -686.8% | 93.3% | 1.3% | 2360.4% | -96.6% | |
| Operating Income | 36.1% | -53.7% | 49.5% | 42.4% | -44.6% | -246.3% | -6.7% | 19.0% | 95.8% | -768.9% | |
| Net Income | 58.2% | -255.3% | 63.3% | 27.8% | -33.6% | -251.1% | -40.3% | 51.9% | 97.6% | -3539.3% | |
| EPS (Diluted) | 60.6% | -253.8% | 65.2% | 31.3% | 9.1% | -100.0% | -20.0% | 58.3% | -130.0% | -1230.4% | |
| Operating Cash Flow | 90.6% | -943.5% | 27.4% | 75.4% | -111.2% | -284.1% | 54.7% | -49.1% | 626.0% | -16095.4% | |
| Free Cash Flow | 89.2% | -811.6% | 28.6% | 75.5% | -110.8% | -284.0% | 54.7% | -49.1% | 626.0% | -16095.4% | |
| R&D Expense | 0.6% | -0.4% | -66.1% | -36.3% | 8.1% | 437.1% | -15.4% | -28.3% | -36.1% | 39271.3% | |
| SG&A Expense | -27.4% | -13.2% | 31.9% | -49.1% | 27.2% | 81.3% | 74.5% | -36.8% | -8.3% | 95600.5% | |
| Total Assets | -1.7% | -26.0% | -21.4% | -37.0% | 72.2% | 60.2% | -70.3% | 42.6% | 57.1% | 65990.3% | |
| Book Value / Share | -6.8% | -60.0% | -7.9% | -32.7% | 186.7% | -8.3% | -76.3% | -2.5% | 15137.4% | 31355.1% | |
| Debt | -14.6% | 11.4% | -24.4% | -29.8% | -92.2% | 6.4% | -16.0% | -53.2% | -17.0% | -84.8% | |
| Diluted Shares | 5.3% | 0.2% | 8.1% | 4.5% | 43.1% | 73.5% | 8.5% | 22.4% | -98.9% | 170.9% |
Valuation
P/E (TTM)At Loss
P/S12.81
10Y Low / Med / High0.74 / 1490.36 / 362590.17
P/B0.61
10Y Low / Med / High0.00 / 330.97 / 1334.09
EV/EBITDA0.38
EV/Revenue-4.08
10Y Low / Med / High338.50 / 16486.88 / 362754.32
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3103.96
Tangible Book / Share
$3.13
Net Current Assets / Share
$3.13
Graham Net-Net
$3.02
Cash / Share
$3.67
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1765.70 | -518.83 | -1585.65 | -2327.56 | -2356.03 | -607.46 | -165.08 | -82.80 | -30.87 | -1.43 | -0.38 | |
| P/S Ratio | 339.18 | 803.16 | 1490.36 | 362590.17 | 16509.26 | 35760.24 | 0.00 | 0.00 | 0.74 | 16.36 | 12.81 | |
| P/B Ratio | 296.19 | 770.00 | 889.20 | 1334.09 | 428.20 | 240.78 | 330.97 | 70.92 | 0.40 | 0.00 | 0.61 | |
| EV/EBITDA | -2502.17 | -428.65 | -982.98 | -9462.15 | -3387.02 | -444.46 | -153.80 | -47.27 | 21.11 | 2169.58 | 0.38 | |
| EV/Revenue | 338.50 | 802.95 | 1490.66 | 362754.32 | 16486.88 | 35674.46 | 0.00 | 0.00 | -0.63 | -16902.47 | -4.08 |
Analyst Estimates & Quality
Altman Z-Score
-6.81
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $609.1K | $57.0M | $57.3M |
| Net Income | -$10.7M | -$10.8M | -$22.2M |
| EPS | $-2.43 | $-2.46 | $-5.05 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2026 |
|---|---|
| Collaborative Arrangement Revenue | $1.2M |